Asosiy kontentga oʻtish
Maqola

Ferroptosis in the Tumor Immune Microenvironment: Mechanisms, Nanomedicine, and Immunotherapy

Usamah SayedFaculty of Allied Medical Sciences, Hourani Center for Applied Scientific Research Al‐Ahliyya Amman University Amman JordanJasur RizaevDepartment of Public Health and Healthcare management Rector, Samarkand State Medical University Samarkand UzbekistanRasul TuraevDepartment of Exact and Natural Sciences Termez State University of Engineering and Agrotechnologies Termez UzbekistanGuzalya MamedovaScientific‐Practical Medical Center for Pediatric Oncology Hematology and Immunology Tashkent UzbekistanSarah Qutayba BadraldinDepartment of Pharmacy Al‐Noor University College Nineveh IraqYsar Mohammed HassanNavin Kumar TailorInstitute of Pharma Sciences Chandigarh University Mohali Punjab IndiaRitesh SinghCentre for Research Impact & Outcome, Chitkara University Institute of Engineering and Technology Chitkara University Rajpura Punjab India
2026en
ABI

Annotatsiya

Ferroptosis, an iron-dependent form of regulated cell death, is frequently dysregulated in both tumor and immune cells, contributing to tumor progression and limiting the effectiveness of cancer immunotherapy. Defining the molecular mechanisms that govern ferroptosis and its effects within the tumor immune microenvironment is critical for understanding its dual role in cancer biology. While modulation of ferroptosis presents a promising therapeutic strategy, non-specific targeting may also impair normal tissues and tumor-infiltrating immune cells. In this context, nanoparticle-based delivery systems offer a potential approach to selectively regulate ferroptosis within tumors. Such strategies may enable precise remodeling of the tumor microenvironment and enhance antitumor immune responses, thereby improving immunotherapy outcomes. This review highlights the regulatory mechanisms linking ferroptosis and the tumor immune microenvironment, provides a critical discussion of recent developments in bionanomaterial-based therapeutic platforms, and outlines the challenges and prospects for clinical application of these platforms for immunotherapy.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar